SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility
The expansion of the Class A zone is an important milestone in SynCo’s strategy in supporting its clients with new product launches in the US and the rest of the world. SynCo’s aseptic filling facility is able to fill and lyophilize a wide range of biopharmaceuticals which include proteins, monoclonal antibodies, polysaccharides, nucleic acids, aluminium containing vaccines, RNA and live biotherapeutics for clinical and market supply.
Announcing this upgrade, Pierre Warffemius, CEO of SynCo Bio Partners said: “The expansion of the Class A zone is an excellent addition to SynCo Bio Partners’ already state-of-the-art contract manufacturing facility in Amsterdam. SynCo is one of the few biopharmaceutical CMOs in the world with a recognized track record in both clinical and commercial manufacturing of both bulk drug substance and drug product and continuously invests in its facilities to achieve its goal: Trust us to make it right.”
Most read news
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.